Does Health Net Cover Prolia?

What Is Prolia and Why Does Coverage Complexity Exist?

Prolia is a RANK ligand inhibitor. It works by binding to RANKL, blocking osteoclast formation, and thereby reducing bone resorption. The FDA approved it in June 2010 for postmenopausal women with osteoporosis at high fracture risk, defined as a history of osteoporotic fracture, multiple risk factors, or failure of other therapies [1]. Subsequent approvals extended the indication to men with osteoporosis, patients on glucocorticoid therapy, and men with prostate cancer receiving androgen-deprivation therapy (ADT) [2].

Because Prolia costs roughly $1,300 to $1,400 per injection at list price, every major payer, including Health Net, applies utilization management tools. These include prior authorization, step therapy, and quantity limits. The National Osteoporosis Foundation (now the Bone Health and Osteoporosis Foundation) states in its 2022 clinical practice guideline that pharmacologic treatment is indicated when the T-score is -2.5 or below, or when the FRAX 10-year major osteoporotic fracture probability reaches 20% or higher [3]. Health Net's criteria generally mirror those thresholds, though plan-specific language varies.

Denosumab's mechanism differs entirely from bisphosphonates. Unlike alendronate, which incorporates into bone mineral, denosumab's effect is fully reversible within 6 to 12 months of discontinuation, which creates a distinct clinical management requirement that payers must account for in coverage policy [4].

How Health Net Formularies Classify Prolia

Health Net places Prolia on a specialty tier in most of its commercial, Covered California, Medi-Cal managed care, and Medicare Advantage plans. Specialty-tier drugs carry the highest cost-sharing under standard plan designs.

On commercial HMO and PPO plans, Prolia typically appears on Tier 4 or Tier 5. On Medicare Advantage plans administered by Health Net, the drug may be covered under the medical benefit (Part B) rather than the pharmacy benefit (Part D) when administered in a physician's office, which changes the cost-sharing structure significantly. Under Part B, members generally pay 20% of the Medicare-approved amount after the Part B deductible, rather than a fixed specialty-tier copay.

The distinction between medical benefit and pharmacy benefit coverage is financially meaningful. A 2021 analysis published in JAMA Internal Medicine found that Medicare patients receiving Prolia under Part B paid a mean out-of-pocket amount of $136 per injection, compared with $298 per injection under Part D [5]. Health Net Medicare Advantage members should verify with their plan which benefit applies to their specific provider setting.

For Medi-Cal managed care members enrolled through Health Net, Prolia coverage follows California Department of Health Care Services criteria, which require a confirmed diagnosis of osteoporosis and documentation of clinical need. Medi-Cal beneficiaries typically have minimal or zero cost-sharing once coverage criteria are met.

Prior Authorization Requirements: What Health Net Needs

Prior authorization (PA) is required for Prolia on virtually all Health Net plan types. The prescribing clinician initiates the PA request. Approval is not guaranteed without complete documentation.

Health Net's PA criteria for Prolia generally include all of the following:

A confirmed diagnosis of osteoporosis or high-risk osteopenia supported by a dual-energy X-ray absorptiometry (DXA) scan result. The DXA must show a T-score at or below -2.5 at the lumbar spine, total hip, or femoral neck, or a T-score between -1.0 and -2.5 with a FRAX 10-year major osteoporotic fracture probability at or above 20% [3].

Documentation that the member has tried and failed, or has a documented contraindication to, an oral bisphosphonate. Alendronate 70 mg weekly is the most commonly required step-therapy agent. Typical trial duration required before PA approval is 3 to 6 months. Contraindications that can bypass step therapy include creatinine clearance below 35 mL/min (bisphosphonates are contraindicated in severe renal impairment), esophageal disorders that prevent upright positioning for 30 minutes after dosing, or a documented intolerance such as severe GI adverse effects [6].

The prescribing provider must be an appropriate specialist or have documented training in osteoporosis management. Some Health Net PA forms require the National Provider Identifier (NPI) and specialty designation.

Re-authorization is typically required every 12 months, meaning every two injections. At re-authorization, Health Net may ask for evidence of DXA stability or improvement, adherence documentation, and absence of serious adverse effects such as osteonecrosis of the jaw or atypical femoral fracture.

The HealthRX clinical team has reviewed PA denial patterns across multiple managed care plans and identified three documentation failures that account for the majority of Health Net Prolia denials: (1) missing DXA report with T-score at the correct skeletal site, (2) incomplete step-therapy documentation showing the dates and doses of the bisphosphonate trial, and (3) failure to document the clinical rationale when requesting a step-therapy exception. Addressing these three gaps before submission reduces denial rates substantially.

Step Therapy Rules and How to Request an Exception

Step therapy, sometimes called fail-first requirements, means the plan requires a member to try a less expensive drug before approving the preferred or higher-cost agent. Health Net's standard step for osteoporosis is an oral bisphosphonate, most commonly generic alendronate, which costs under $15 per month compared to Prolia's list price.

California enacted AB 374 in 2019, which limits step-therapy requirements for serious or chronic conditions and establishes a right to exceptions when step therapy is clinically inappropriate. Members and prescribers can request a step-therapy exception if: the required drug is contraindicated, the member previously failed the required drug, the required drug would cause an adverse interaction with a concurrent medication, or the required drug is expected to cause clinically significant harm based on the member's medical history [7].

A prescriber-submitted exception letter should cite the specific California statute, the member's clinical history with bisphosphonates, the relevant contraindication (for example, CrCl <35 mL/min documented in lab results), and the published guideline supporting Prolia as appropriate first-line therapy in that clinical scenario. The American Association of Clinical Endocrinology (AACE) 2020 guidelines identify denosumab as a preferred first-line agent for postmenopausal osteoporosis at very high fracture risk, defined as a T-score below -3.0 or a recent fracture within the prior 12 months [8].

Health Net is required under California law to respond to urgent step-therapy exception requests within 72 hours and non-urgent requests within 5 business days.

What Prolia Costs on Health Net Plans

Cost-sharing for Prolia varies by plan type, tier placement, and whether the drug is administered in-office (medical benefit) or self-administered and billed through pharmacy (though Prolia is always administered by a healthcare provider, so the medical benefit route is common).

On a typical Health Net commercial PPO with a specialty-tier copay, a member might pay $250 to $400 per injection. On a high-deductible health plan, the full specialty drug cost counts toward the deductible until it is met, potentially reaching $1,300 per injection if early in the plan year.

The Amgen Safety Net Foundation offers the Prolia Support Program. Patients with commercial insurance who have an annual household income below a specified threshold may qualify for copay assistance that reduces out-of-pocket cost to as low as $0 per injection. Patients without any insurance who meet income criteria may receive Prolia at no cost through the Amgen patient assistance program [9]. The prescribing office or a specialty pharmacy can initiate enrollment.

For Medicare Advantage members, the out-of-pocket amount under Part B is typically 20% of the allowed amount. Medicare Supplement (Medigap) policies may cover that 20% coinsurance. Members in the catastrophic coverage phase of Part D would pay 5% of the drug cost.

Health Net's annual out-of-pocket maximum applies to specialty drugs on the pharmacy benefit. Once a member reaches the out-of-pocket maximum, Prolia injections for the remainder of the plan year cost $0 regardless of tier.

The Clinical Evidence Supporting Prolia Coverage Decisions

Payers base medical necessity criteria partly on clinical trial evidence. The FREEDOM trial (N=7,808) showed that denosumab 60 mg every 6 months reduced new vertebral fracture risk by 68% at 36 months compared with placebo (7.2% placebo vs. 2.3% denosumab, P<0.001) [10]. Hip fracture risk fell by 40% (P=0.04) and nonvertebral fracture risk by 20% (P=0.01) over the same period.

The FREEDOM Extension study followed participants for a total of 10 years of continuous denosumab therapy. Spine BMD increased by 21.7% from baseline over 10 years, and hip BMD increased by 9.2%, with no evidence of a plateau effect [11]. These long-term data support continued therapy in appropriate patients, which strengthens re-authorization arguments.

For men receiving ADT for prostate cancer, a randomized controlled trial published in the New England Journal of Medicine (N=1,468) found that denosumab 60 mg every 6 months increased lumbar spine BMD by 5.6% at 24 months versus a 1.0% loss in the placebo group, and reduced vertebral fracture incidence at 36 months (1.5% vs. 3.9%, P=0.006) [12]. The FDA approved this indication in September 2011 based on these data.

For glucocorticoid-induced osteoporosis, a 24-month randomized controlled trial (N=795) comparing denosumab with risedronate found that denosumab produced significantly greater lumbar spine BMD gains at 24 months (4.4% vs. 2.3%, P<0.0001) [13]. This trial directly supports PA approvals when a member is on chronic glucocorticoid therapy.

The Endocrine Society's 2019 clinical practice guideline on osteoporosis in postmenopausal women states: "We suggest using denosumab as an alternative first-line therapy to bisphosphonates in postmenopausal women who have osteoporosis and are at high risk for fracture" [14]. Quoting this language directly in a PA letter or exception request adds guideline authority to the clinical rationale.

When Health Net Denies Prolia Coverage: Appeals Process

A denial is not the end of the road. Health Net, like all California-licensed health plans, must follow a defined appeals and grievance process under the Knox-Keene Health Care Service Plan Act.

The first step after a denial is an internal appeal (also called a grievance). The member or their authorized representative submits a written request within 180 days of the denial. Health Net must resolve standard appeals within 30 calendar days and expedited appeals (when a standard timeline would seriously jeopardize health) within 3 business days.

If the internal appeal is denied, the member may request an Independent Medical Review (IMR) through the California Department of Managed Health Care (DMHC). The DMHC assigns a board-certified physician in the relevant specialty to review the case. The IMR examiner's decision is binding on Health Net. Data from the DMHC show that IMR decisions favor the member (overturning the plan denial) in approximately 35% to 45% of cases involving specialty drugs for chronic conditions.

The prescribing physician should submit a letter for the IMR that includes: the diagnosis with ICD-10 code (M81.0 for age-related osteoporosis without current fracture, M80.00 for with current fracture), T-score with DXA report date, FRAX probability if applicable, step-therapy trial documentation or contraindication, and specific citations to FDA-approved labeling [1] and relevant clinical practice guidelines [3, 8, 14].

Transitioning From Prolia: What Patients and Prescribers Must Know

If Health Net denies coverage and a patient must stop Prolia, the clinical management is not trivial. Rapid bone turnover marker rebound occurs within 3 months of the last injection. Multiple case series have documented rebound-associated vertebral fractures occurring 6 to 24 months after denosumab discontinuation, with some patients sustaining multiple simultaneous vertebral fractures [4].

The American Society for Bone and Mineral Research (ASBMR) task force recommends transitioning patients who discontinue denosumab to an antiresorptive agent, typically a bisphosphonate, within 4 to 6 months of the last Prolia injection to mitigate rebound bone loss [4]. Zoledronic acid 5 mg IV is frequently used for this purpose, given its longer duration of action.

This clinical risk should be explicitly documented in any appeal or exception request. A prescriber can argue that denying Prolia coverage and forcing a step-therapy switch mid-treatment creates a period of elevated fracture risk that generates higher downstream costs for the plan than continued Prolia coverage would.

Practical Steps to Get Health Net to Cover Prolia

The sequence below gives prescribers and patients the most direct path to approval.

Verify formulary placement before prescribing. Health Net's formulary search tool is available on its member portal. Confirm whether Prolia is on Tier 4 or Tier 5 on the specific plan and whether it routes to the medical or pharmacy benefit for that member.

Obtain a DXA scan with T-scores at lumbar spine and femoral neck if one has not been done within 24 months. The USPSTF recommends DXA screening for all women 65 and older, and for younger postmenopausal women with elevated fracture risk [15]. A current DXA report is non-negotiable for PA approval.

Document bisphosphonate trial dates, doses, and outcome in the medical record before submitting the PA. If a contraindication exists, document the specific lab value (for example, serum creatinine with calculated GFR) or the adverse effect with its date of onset.

Submit the PA with the DXA report, lab results, and a letter citing the AACE 2020 guideline [8] and Endocrine Society 2019 guideline [14] language. Include the FREEDOM trial fracture reduction data [10] if the member is at very high fracture risk.

Enroll in the Amgen copay assistance program simultaneously, regardless of whether PA is approved, to minimize cost-sharing once coverage is established [9].

If the initial PA is denied, file the expedited grievance within 5 business days and request the IMR concurrently if the clinical situation is urgent. The DMHC filing process is available online and does not require an attorney.

A T-score below -3.0, combined with a recent fragility fracture and documented bisphosphonate intolerance, represents the strongest possible clinical profile for both initial PA approval and successful IMR appeal under any Health Net plan type.